Seasonal allergic rhinitis: Fluticasone propionate and fluticasone furoate therapy evaluated

Journal of Asthma and Allergy

Volumn 3, Issue , 2010, Pages 19-28

  Kariyawasam, Harsha H ^a   Scadding, Glenis K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Fluticasone furoate; Fluticasone propionate; Seasonal allergic rhinitis

Indexed keywords

EID: 85014552132     PISSN: None     EISSN: 11786965     Source Type: Journal    
DOI: 10.2147/JAA.S6698     Document Type: Review

References (92)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86: 8-160.
2. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007;62 Suppl 85:17-25.
3. Emanuel MB. Hay fever, a post industrial revolution epidemic: a history of its growth during the 19th century. Clin Allergy. 1988;18:295-304.
4. Strachan DP. Epidemiology of hay fever: towards a community diagnosis. Clin Exp Allergy. 1995;25:296-303.
5. von Mutius E, Weiland SK, Fritzsch C, Duhme H, Keil U. Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany. Lancet. 1998;351:862-866.
6. Bousquet PJ, Chinn S, Janson C, Kogevinas M, Burney P, Jarvis D. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy. 2007;62:301-309.
7. Scadding GK, Kariyawasam HH. Airways disease: just nosing around? Thorax. 2009;64:923-925.
8. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38:19-42.
9. Rondon C, Fernandez J, Lopez S, et al. Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis. J Allergy Clin Immunol. 2009;124:1005-1011.
10. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, Pallestrini E, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy. 2005;60:882-887.
11. Naclerio RM, Pinto J, deTineo M, Baroody FM. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc. 2008;29:24-28.
12. Portnoy JM, Van Osdol T, Williams PB. Evidence-based strategies for treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2004;4:439-446.
13. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ. 1998;317:1624-1629.
14. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89:479-484.
15. Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med. 2004;116:338-344.
16. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol. 1998;81:478-518.
17. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122:S1-S84.
18. Leynaert B, Neukirch C, Kony S, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol. 2004;113:86-93.
19. Madonini E, Briatico-Vangosa G, Pappacoda A, Maccagni G, Cardani A, Saporiti F. Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol. 1987;79:358-363.
20. Corren J, Adinoff AD, Buchmeier AD, Irvin CG. Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol. 1992;90:250-256.
21. Aubier M, Levy J, Clerici C, Neukirch F, Herman D. Different effects of nasal and bronchial glucocorticosteroid administration on bronchial hyperresponsiveness in patients with allergic rhinitis. Am Rev Respir Dis. 1992;146:122-126.
22. Stelmach R, do Patrocinio TN, Ribeiro M, Cukier A. Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma. Chest. 2005;128:3140-3147.
23. Murray JR. The history of corticosteroids. Acta DermVenereol Suppl (Stockh). 1989;151:4-6.
24. Hench PS, Kendall EC. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc. 1949;24:181-197.
25. Katz M, Gans EH. Topical corticosteroids, structure-activity and the glucocorticoid receptor: discovery and development-a process of “planned serendipity”. J Pharm Sci. 2008;97:2936-2947.
26. Brown HM, Storey G, George WH. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma. Br Med J. 1972;1:585-590.
27. Mygind N. Local effect of intranasal beclomethasone dipropionate aerosol in hay fever. Br Med J. 1973;4:464-466.
28. Turkeltaub PC, Norman PS, Crepea S. Treatment of ragweed hay fever with an intranasal spray containing fluinsolide, a new synthetic corticosteroid. J Allergy Clin Immunol. 1976;58:597-606.
29. Balle VH, Pedersen U, Engby B. Allergic perennial and non-allergic, vasomotor rhinitis treated with budesonide nasal spray. Rhinology. 1980;18:135-142.
30. Meltzer EO, Orgel HA, Bronsky EA, et al. A dose-ranging study of fluticasone propionate aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology. J Allergy Clin Immunol. 1990;86:221-230.
31. Findlay S, Huber F, Garcia J, Huang L. Efficacy of once-a-day intranasal administration of triamcinolone acetonide in patients with seasonal allergic rhinitis. Ann Allergy. 1992;68:228-232.
32. Schmidt BM, Timmer W, Georgens AC, et al. The new topical steroid ciclesonide is effective in the treatment of allergic rhinitis. J Clin Pharmacol. 1999;39:1062-1069.
33. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active-and placebo-controlled study. Allergy. 1996;51:569-576.
34. Bikowski J, Pillai R, Shroot B. The position not the presence of the halogen in corticosteroids influences potency and side effects. J Drugs Dermatol. 2006;5:125-130.
35. Popper TL, Gentles MJ, Kung TT, et al. Structure-activity relationships of a series of novel topical corticosteroids. J Steroid Biochem. 1987;27:837-843.
36. Phillipps GH, Bailey EJ, Bain BM, et al. Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogues, halomethyl androstane-17 beta-carbothioates and-17 beta-carboselenoates. J Med Chem. 1994;37:3717-3729.
37. Dahlberg E, Thalen A, Brattsand R, et al. Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. Mol Pharmacol. 1984;25:70-78.
38. Buchwald P. Glucocorticoid receptor binding: a biphasic dependence on molecular size as revealed by the bilinear LinBiExp model. Steroids. 2008;73:193-208.
39. Pujolsa L, Mullol J, Picado C. Glucocorticoid receptor in human respiratory epithelial cells. Neuroimmunomodulation. 2009;16:290-299.
40. Bryson HM, Faulds D. Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs. 1992;43:760-775.
41. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994;59:597-602.
42. Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8:54.
43. Daley-Yates PT, Baker RC. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Br J Clin Pharmacol. 2001;51:103-105.
44. Falcoz C, Oliver R, McDowall JE, Ventresca P, Bye A, Daley-Yates PT. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39 Suppl 1:9-15.
45. Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1996;41:539-542.
46. Pearce RE, Leeder JS, Kearns GL. Biotransformation of fluticasone: in vitro characterization. Drug Metab Dispos. 2006;34:1035-1040.
47. Harding SM. The human pharmacology of fluticasone propionate. Respir Med. 1990;84 Suppl A:25-29.
48. LaForce CF, Dockhorn RJ, Findlay SR, et al. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract. 1994;38:145-152.
49. Dolovich J, O’Connor M, Stepner N, Smith A, Sharma RK. Double-blind comparison of intranasal fluticasone propionate, 200 micrograms, once daily with 200 micrograms twice daily in the treatment of patients with severe seasonal allergic rhinitis to ragweed. Ann Allergy. 1994;72:435-440.
50. Pedersen B, Dahl R, Richards DH, et al. Once daily fluticasone propionate aqueous nasal spray controls symptoms of most patients with seasonal allergic rhinitis. Allergy. 1995;50:794-99.
51. Dykewicz MS, Kaiser H., Nathan RA, et al. Fluticasone propionate aqueous nasal spray improves nasal symptoms of seasonal allergic rhinitis when used as needed (prn). Ann Allergy Asthma Immunol. 2003;91:44-48.
52. Meltzer EO, Rickard KA, Westlund RE, Cook CK. Onset of therapeutic effect of fluticasone propionate aqueous nasal spray. Ann Allergy Asthma Immunol. 2001;86:286-291.
53. Boner A, Sette L, Martinati L, Sharma RK, Richards DH. The efficacy and tolerability of fluticasone propionate aqueous nasal spray in children with seasonal allergic rhinitis. Allergy. 1995;50:498-505.
54. Grossman J, Banov C, Bronsky EA, et al. Fluticasone propionate aqueous nasal spray is safe and effective for children with seasonal allergic rhinitis. Pediatrics. 1993;92:594-599.
55. Munk ZM, Pearlman D, Graft D, et al. Intranasal fluticasone propionate is effective and well-tolerated in adolescents with seasonal allergic rhinitis. Pediatr Asthma Allergy Immunol. 1994;8:39-46.
56. Keith P, Nieminen J, Hollingworth K, Dolovich J. Efficacy and tolerability of fluticasone propionate nasal drops 400 microgram once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy. 2000;30:1460-1468.
57. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:L660-L667.
58. Allen A, Down G, Newland A, et al. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects. Clin Ther. 2007;29:1415-1420.
59. Hughes SC, Shardlow PC, Hollis FJ, et al. Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos. 2008;36:2337-2344.
60. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc. 2007;28:216-225.
61. Fokkens WJ, Jogi R, Reinartz S, et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy. 2007;62:1078-1084.
62. Kaiser H., Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;119:1430-1437.
63. Jacobs R, Martin B, Hampel F, Toler W, Ellsworth A, Philpot E. Effectiveness of fluticasone furoate 110 mug once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin. 2009;25:1393-1401.
64. Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin. 2009;25:2021-2041.
65. Baroody FM, Shenaq D, deTineo M, Wang J, Naclerio RM. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol. 2009;123:1342-1348.
66. Baumann D, Bachert C, Hogger P. Dissolution in nasal fluid, retention and anti-inflammatory activity of fluticasone furoate in human nasal tissue ex vivo. Clin Exp Allergy. 2009;39:1540-1550.
67. Raap U, Braunstahl GJ. The role of neurotrophins in the pathophysiology of allergic rhinitis. Curr Opin Allergy Clin Immunol. 2010;10:8-13.
68. Meltzer EO, Lee J, Tripathy I, Lim J, Ellsworth A, Philpot E. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 weeks. Pediatr Allergy Immunol. 2009;20:279-286.
69. Skoner JD, Schaffner TJ, Schad CA, Kwon AY, Skoner DP. Addressing steroid phobia: improving the risk-benefit ratio with new agents. Allergy Asthma Proc. 2008;29:358-364.
70. Bruni FM, De Luca G, Venturoli V, Boner AL. Intranasal corticosteroids and adrenal suppression. Neuro immuno modulation. 2009;16: 353-362.
71. van As A, Bronsky E, Grossman J, Meltzer E, Ratner P, Reed C. Dose tolerance study of fluticasone propionate aqueous nasal spray in patients with seasonal allergic rhinitis. Ann Allergy. 1991;67:156-162.
72. Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1998;102:191-197.
73. Haye R, Gomez EG. A multicentre study to assess long-term use of fluticasone propionate aqueous nasal spray in comparison with beclomethasone dipropionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinology. 1993;31:169-174.
74. Howland WC III. Fluticasone propionate: topical or systemic effects? Clin Exp Allergy. 1996;26 Suppl 3:18-22.
75. Scadding GK, Lund VJ, Holmstrom M, Darby YC. Clinical and physiological effects of fluticasone propionate aqueous nasal spray in the treatment of perennial rhinitis. Rhinol Suppl. 1991;11:37-43.
76. Richards DH, Milton CM. Fluticasone propionate aqueous nasal spray: a well-tolerated and effective treatment for children with perennial rhinitis. Pediatr Allergy Immunol. 1996;7:35-43.
77. Treatment of seasonal allergic rhinitis with once-daily intranasal fluticasone propionate therapy in children. Fluticasone Propionate Collaborative Pediatric Working Group. J Pediatr. 1994;125:628-634.
78. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy. 2007;62:1071-1077.
79. Tripathy I, Levy A, Ratner P, Clements D, Wu W, Philpot E. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol. 2009;20:287-294.
80. Maspero JF, Rosenblut A, Finn A Jr, Lim J, Wu W, Philpot E. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otolaryngol Head Neck Surg. 2008;138:30-37.
81. Meltzer EO, Tripathy I, Maspero JF, Wu W, Philpot E. Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies. Clin Drug Investig. 2009;29:79-86.
82. Gradman J, Caldwell MF, Wolthers OD. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin Ther. 2007;29:1738-1747.
83. Khanna P, Shah A. Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. Am J Rhinol. 2005;19:316-321.
84. Mahadevia PJ, Shah S, Leibman C, Kleinman L, O’Dowd L. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Ann Allergy Asthma Immunol. 2004;93:345-350.
85. Meltzer EO, Bardelas J, Goldsobel A, Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat Respir Med. 2005;4:289-296.
86. Bousquet J, Van Cauwenberge P, Bachert C, et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy. 2003;58:192-197.
87. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol. 2003;117:843-845.
88. Baroody FM, Cheng CC, Moylan B, et al. Absence of nasal mucosal atrophy with fluticasone aqueous nasal spray. Arch Otolaryngol Head Neck Surg. 2001;127:193-199.
89. Stokes M, Amorosi SL, Thompson D, Dupclay L, Garcia J, Georges G. Evaluation of patients’ preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg. 2004;131:225-231.
90. Bachert C, El Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2002;89:292-297.
91. Daley-Yates PT, Richards DH. Relationship between systemic corticosteroid exposure and growth velocity: development and validation of a pharmacokinetic/pharmacodynamic model. Clin Ther. 2004;26:1905-1919.
92. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv. 2007;4:689-701.